← Back to libraryEntry · LZH-002

lyophilized

GIP / GLP-1 · Dual receptor agonist

Tirzepatide

Dual GIP and GLP-1 receptor agonist

Technical datasheetLZH-002

Code: GIP / GLP-1
Formula: C225H348N48O68
Molecular weight: 4813.5 Da
Half-life: ~120 h (≈ 5 days)
Research route: Subcutaneous (research)
Molecular targets: GIPR · GLP-1R
Discovery / disclosure: Disclosed 2018, Eli Lilly
Target purity: ≥ 98%
Recommended storage: −20°C, light protected. 2 to 8°C after reconstitution.

Aliases

LY3298176, Mounjaro, Zepbound

Appearance

White lyophilized powder

Solubility

Soluble in phosphate buffer pH 7-8

Sequence

YAibEGTFTSDYSIaibLDKIAQK(γE-2xOEG-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH2

Analysts reviewing the HPLC chromatogram for the current batch — FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.

Technician monitoring a stainless steel reactor during scale-up — FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.

Overview

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, a 39 amino acid synthetic peptide that activates two incretin pathways simultaneously.

Pharmacology and mechanism

GIP receptor co-activation enhances insulin secretion, improves lipid metabolism and modulates adipose tissue, stacking with GLP-1 effects for stronger metabolic and body weight outcomes.

Research areas

R.01

Dual GIP and GLP-1 receptor agonist

Studied in metabolic syndrome, obesity and type 2 diabetes models, and explored for NASH and combined cardiometabolic risk intervention.

Structural notes

39 amino acid modified peptide with a C20 diacid fatty side chain anchoring an albumin-binding domain for weekly pharmacokinetics.

Sequence

YAibEGTFTSDYSIaibLDKIAQK(γE-2xOEG-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH2

For research use only. Not medical advice. Not for diagnosis or treatment.

Related molecules

Triple receptor agonist

Open →

Elamipretide639.8 Da

SS-31

Mitochondrial targeting

CJC-1295 + Ipamorelin

Regenerative research

Open →